Loading
Life sciences · Journal article
Nano Letters · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Controllable synthesis of two-dimensional (2D) platinum (Pt)-based nanomaterials with high photothermal conversion property for near-infrared (NIR) photothermal tumor therapy (PTT) is highly desired yet challenging. Herein, we report iodide (I–)-engineered Pt-antimony nanosheets (PtSbI NSs) with an ultrathin banana-slice-shaped profile for PTT. These PtSbI NSs exhibit dual phototherapeutic functions including outstanding photothermal conversion efficiency (49.6%) versus PtSbI nanoparticles (24.2%), PtSb NSs (29.0%), and commercial Au NSs (10.7%) as well as excellent photothermal stability. When functionalized with aptamers targeting the tumor biomarker EpCAM, they can serve as a tumor-targeted nanozyme. Through reactive oxygen species generation, they effectively mitigate tumor hypoxia, induce selective tumor cell apoptosis, and facilitate synergistic photothermal–catalytic therapy, leading to an 83.3% reduction in tumor weight and a significant extension of survival in 4T1 breast cancer-bearing mice. This work is of great significance for advancing the synthesis and functionalization of 2D Pt-based nanomaterials employed in the PTT field and beyond.